MedTrace Logo

A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood

NCT05934942 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2025-02-24

Study results available
· View outcomes & findings →

Summary

This study aims to investigate the effect of multiple doses of BI 1358894 on pharmacokinetics of ethinylestradiol (EE) and drospirenone (DRSP) (Yasmin®)

Conditions

  • Healthy

Interventions

DRUG

Yasmin®

Ethinylestradiol (EE) and Drospirenone (DRSP)

DRUG

BI 1358894

BI 1358894

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-08
Primary Completion
2024-02-08
Completion
2024-02-08

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05934942 on ClinicalTrials.gov